

Emerging Role of Antibody-Drug Conjugates in the Management of Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Based on the results of the DESTINY-Lung01 study, which subset of patients experienced the highest overall response rate (ORR) with trastuzumab deruxtecan (T-DXd)?
 - a. Those with HER2-amplified disease
 - b. Those with HER2-mutant disease**
 - c. Those with HER2-overexpressing disease
 - d. ORR was similar across all subsets
2. What was observed regarding adjudicated drug-related interstitial lung disease (ILD) in the DESTINY-Lung01 study evaluating T-DXd?
 - a. Median time to onset of ILD was 7 days
 - b. ILD was Grade 3 in the majority of patients in which it was observed
 - c. All patients experiencing ILD had T-DXd withdrawn**
3. What was observed in a Phase I dose-escalation/expansion study of patritumab deruxtecan for patients with locally advanced or metastatic non-small cell lung cancer with an EGFR mutation who had undergone prior EGFR tyrosine kinase inhibitor therapy?
 - a. Responses were only observed in patients with EGFR-activating mutations
 - b. Responses were only observed in patients with EGFR T790M mutations
 - c. Responses were observed in patients with a range of EGFR and non-EGFR mutations**
4. Which of the following drug types best describes the mechanism of action of datopotamab deruxtecan?
 - a. Anti-TROP2 antibody-drug conjugate**
 - b. Anti-HER2 antibody-drug conjugate
 - c. Anti-CEACAM5 antibody-drug conjugate
 - d. Anti-HER3 antibody-drug conjugate
5. Which of the following adverse events was most frequently observed in the TROPION-PanTumor01 study of datopotamab deruxtecan?
 - a. Hematologic adverse events, particularly cytopenias
 - b. Stomatitis**
 - c. ILD/pneumonitis